Virtual Screening and ADME/Pharmacokinetic Studies of Triclosan Analogs as Inhibitors of the FabI Protein from Plasmodium falciparum

Abstract

Malaria, caused by Plasmodium falciparum, remains a significant global health crisis, further compounded by the rise of drug-resistant strains. The FabI enzyme, integral to the fatty acid biosynthesis pathway in P. falciparum, represents a promising target for novel antimalarial drug development. This study focuses on evaluating triclosan analogs as potential inhibitors of FabI.